3rd Circ. Ends Amarin Shareholder Row Over Heart Drug
The Third Circuit upheld the dismissal of a securities class action against biopharmaceuticals maker Amarin on Tuesday, agreeing with a New Jersey district court that the company's statements about the FDA...To view the full article, register now.
Already a subscriber? Click here to view full article